Dietary Supplement Manufacturing Registration in Indonesia: Ownership, KBLI, Licences, and Cost

Separate ownership eligibility from the product route

A foreign investor can manufacture some dietary supplements in Indonesia, but not by choosing any code that happens to mention supplements. Presidential Regulation 49/2021 establishes the general open-to-investment rule, while its investment schedules preserve activity-specific restrictions. Foreign ownership must be tested against the exact KBLI . The test must then be repeated against the planned product, dosage form and actual production process.

For the current KBLI 2025 system, OSS describes KBLI 21012 as human pharmaceutical product manufacturing and expressly includes finished health or food supplements in forms such as tablets, capsules, powders, solutions and suspensions. The OSS page also lists relevant supporting licences, including Good Manufacturing Practice for medicines and BPOM health-supplement services. KBLI 21012 is not listed as a domestic-capital-only activity in Annex III of the investment schedule, so it is the principal code to assess for a genuinely pharmaceutical, foreign-owned production plan. That conclusion remains conditional on the current OSS scope and sector approvals for the exact project.

By contrast, OSS describes KBLI 21022 as traditional-medicine products for humans and includes non-pharmaceutical health or food supplements. Annex III of the investment regulation places KBLI 21022, together with 21021, in the 100% domestic-capital category. A PT PMA should therefore not use 21022 as a shortcut for a foreign-owned herbal or natural-product factory. Nominee shareholding does not cure the underlying mismatch. A lawful alternative may be a properly classified 21012 operation, a genuinely eligible food-industry route, or contract manufacture, but only when the product and process support that route.

Entity formation and factory licensing are related but separate workstreams. The deed, AHU approval, tax registration and OSS identity should reflect the chosen activity before sector submissions begin; the general sequence is explained in Indonesia company formation requirements . Completion of the company layer does not mean that the plant may manufacture or release a supplement.

Classify the product before selecting a KBLI

The commercial label “dietary supplement” is not enough to select a licence route. Freeze a regulatory product brief first: every active and excipient, source of each ingredient, daily dose, dosage form, claims, target consumer, pack presentation, manufacturing steps and whether the product is sterile. A capsule with a pharmacological-style formula, a gummy made in a food plant and a herbal liquid may reach BPOM through different facility standards even when the marketing team treats all three as one portfolio.

A KBLI is not a substitute for a product classification or a BPOM manufacturing route. The code describes the business activity; the facility standard proves manufacturing capability; and the product registration assesses the formula, safety, benefit, quality and label. All three must agree.

BPOM’s official health-supplement standards FAQ identifies pharmaceutical, traditional-medicine and food manufacturers as possible producer types, subject to their respective CPOB, CPOTB and CPPOB evidence. It also narrows the food-facility pathway to specified forms such as oral liquids, powders prepared as liquids and gummies, and requires a separate approval for producing supplements in a food facility. Treat that FAQ as a routing checkpoint; the final dossier must follow the current regulation and the service displayed in the application portal.

Test the site before capital and equipment commitments

A suitable industrial building is not established by a landlord’s marketing description. Before signing an unconditional lease or ordering a production line, map the land and building evidence to the KBLI, scale, utilities, emissions, wastewater, hazardous or non-hazardous waste, storage loads, personnel and material flows, fire strategy and expansion plan. The OSS risk-based licensing framework now rests on Government Regulation 28/2025 , which replaced Government Regulation 5/2021. The actual OSS outputs depend on the activity, scale and project data entered.

Environmental approval is not a generic document that can be borrowed from an estate or previous tenant. Government Regulation 22/2021 covers environmental approvals as well as water, air and hazardous and non-hazardous waste controls. Determine whether the project requires AMDAL, UKL-UPL or another applicable instrument from the activity and thresholds actually planned, then align the technical design with the resulting commitments. The building workstream should separately verify lawful use, the applicable building approval and the evidence needed before occupation and operation.

The useful comparison is not “cheap lease versus expensive lease.” It is “site that can carry the approved process versus site that forces a redesign.” The nutraceutical factory approval sequence gives additional context for keeping entity, industrial site and approvals on one critical path.

• Obtain the land-right or lease evidence, spatial-use result and permitted industrial use before making the lease unconditional.
• Reconcile the architectural plan with hygienic zoning, quarantine, sampling, rejected-goods, change rooms and pest-control boundaries.
• Size water, ventilation, temperature or humidity control and waste systems against the intended product and batch scale.
• Use conditions precedent for unresolved zoning, environmental, building and BPOM facility assumptions.

Build the BPOM facility and product approval chain

BPOM product registration sits near the end of a chain, not at the beginning. Under BPOM Regulation 32/2022 , as amended, supplements made or imported for circulation in Indonesia are assessed for safety, benefit, quality and labelling. A valid submission therefore needs a responsible applicant, a qualified manufacturing site and a coherent product dossier. A product number cannot compensate for a facility whose approved scope does not cover the dosage form.

Sequence for an own-factory route

1. Lock the formula, dosage form, claims, target population and product category; identify any novel material or elevated-evidence issue.
2. Confirm shareholder eligibility, establish the entity and align the deed, AHU records, tax data, NIB, KBLI, address and project scale.
3. Complete the site, environmental and building dependencies and design the facility to the selected GMP regime.
4. Appoint the required technically responsible personnel and build the quality system, including supplier qualification, specifications, validation, deviations, change control, complaints and recall readiness.
5. Obtain the facility certificate or approval for the relevant dosage form and production scope; preserve the portal output and approved scope, not only a screenshot of status.
6. Submit pre-registration and the product dossier, respond to questions without changing the commercial formula off-system, then obtain the product authorisation before release to market.

For a food-industry route, BPOM’s FAQ states that the food facility needs CPPOB and an approval to produce health supplements. A new or changed facility may be inspected, and the approval is time-limited and renewable. For a contract route, the manufacturer’s certificate and scope must cover the product, while the agreement must allocate dossier access, change notifications, batch release, complaints, recalls, retention samples and adverse-event information. The applicant should verify the manufacturer’s approved dosage-form scope , not merely collect a certificate copy.

Completion evidence

Treat the chain as complete only when the company and site records agree, the facility approval names the correct operator and scope, the BPOM product authorisation covers the final formula and label, and the release procedure prevents unapproved stock from entering commerce. Save machine-readable portal outputs, signed technical documents, payment receipts, inspection correspondence and the final approved artwork in a controlled index.

Price the known government charges without inventing a factory total

The official amounts below are national non-tax revenue charges, not a complete factory budget. Government Regulation 15/2026 took effect on 26 May 2026 and replaced the previous BPOM PNBP schedule. The regulation’s appendix prices each service item; the route and number of products determine which items apply. Land, construction, equipment, utilities, laboratory work, validation, professional services, translations, taxes and corrective work are separate.

A simple regulatory-fee scenario illustrates the difference. One vitamin/mineral product on a new CPOB dosage-form route has listed PNBP of IDR 20,100,000: IDR 15,000,000 for the new CPOB certification, IDR 100,000 for pre-registration and IDR 5,000,000 for the product registration. That arithmetic assumes those exact services apply and does not include the plant, testing, validation or any other licence. Three products do not automatically multiply the facility certificate, but they normally create separate pre-registration and registration items.

HSJGlobal’s approved corporate benchmark should also be read narrowly. PT PMA Essential is IDR 29,500,000 one-time, excluding VAT where lawfully chargeable, and was approved for publication on 7 September 2026. It covers a standard single PT PMA with one location and up to two low- or medium-low-risk KBLIs, including AHU application support and AHU PNBP up to IDR 5,000,000. A regulated supplement factory under KBLI 21012 falls outside that package’s stated eligibility, so IDR 29,500,000 is a comparator for the corporate layer—not a quote for this factory. Sector licensing, site, environmental and building approvals, BPOM work, overseas documents, bank, tax, immigration and operating capital require separate scoping.

Assemble the evidence file around each regulatory assertion

A long document list is less useful than an evidence map. Assign every assertion in the application to an owner, source, approval state and completion test. Corporate records prove who operates and applies; site records prove lawful control and suitable use; quality records prove controlled manufacture; product records prove what will be sold. Keep names, addresses, KBLI descriptions and responsible-person details consistent across these groups.

Version control matters because early procurement decisions often change the dossier. Give the regulatory brief a controlled identifier; require engineering, procurement and marketing to cite that version; and log each change to ingredient, claim, supplier, process, room, equipment or pack. A change is not merely “commercial” when it alters the approved product or facility evidence.

Use a completion register with the official service name, applicant, application ID, payment evidence, submission date, current status, approved scope, issue and expiry dates, conditions and renewal owner. An application receipt is not an operating authorisation. The closing record is the final valid output and its conditions, reconciled to the asset and product that will actually operate.

Compare build, contract manufacture, and route redesign

The best structure depends on what creates competitive advantage. Owning a plant can protect process know-how and capacity, but it concentrates site, qualification and utilisation risk. Contract manufacture can reduce fixed commitment and accelerate evidence gathering, but it creates dependence on another company’s approved scope, data access and change discipline. Redesigning a product into an eligible route may simplify one gate, yet it is lawful only when the final formula, form and process genuinely meet that route—not when the paperwork is changed around an unchanged product.

Run a two-stage decision, not a single incorporation decision

Stage one is a route-feasibility gate: product brief, ownership, KBLI, site class, facility standard and BPOM service are mutually consistent. Stage two is an investment gate: the regulatory path is reflected in land and building conditions, equipment specifications, staffing, validation, launch timing and downside funding. A board approval that covers only incorporation leaves the largest risks unpriced.

Choose contract manufacture when it answers the real uncertainty—usually demand, dosage-form capability or time to validated production—rather than merely hiding an ownership restriction. Choose an own plant when the exact site and technical design can reach the relevant GMP scope and the business can carry the pre-revenue period. Escalate the classification when ingredients, claims or dosage form sit near category boundaries, or when a foreign-owned entity would otherwise depend on a domestic-only code.

Apply the go or no-go test to the supplement factory

Proceed with an Indonesian supplement plant only when one signed route record connects the final product brief to a foreign-ownership-eligible KBLI, the selected site, the applicable facility standard, the BPOM product path and a budget that separates known PNBP from unquoted project costs. For a PT PMA, that normally means testing KBLI 21012 first when the product is truly within its pharmaceutical scope; KBLI 21022 should be treated as domestic-capital-only under the current investment schedule.

The immediate priority is to obtain a product-classification and ownership view before an unconditional lease, equipment order or nominee arrangement. Pause and obtain case-specific confirmation if the formula or claims are unsettled, the intended food-facility dosage form is outside BPOM’s stated route, the OSS scope differs from the deed, or a manufacturer cannot show approval for the exact dosage form. The go decision is evidence that the same project can pass every gate—not simply the existence of an NIB or a BPOM submission number.